FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597884013> ?p ?o ?g. }

• W2597884013 abstract "Abstract Abstract 1772 CD49d (α4 integrin chain) is a strong negative prognosticator in chronic lymphocytic leukemia (CLL) with a key role in CLL cell microenvironmental interactions. CD49d triggering by its main ligands Vascular Cell Adhesion Molecule-1 (VCAM-1) and non-RGD sites (CS-1 fragments) of fibronectin (FN) activates signalling pathways delivering pro-survival signals, and promoting resistance to drug-induced apoptosis in CLL. Recently, the globular (g) C1q-like domain of Elastin MIcrofibriL INterfacer1 (EMILIN1), an adhesive extracellular matrix constituent, was described as a new ligand for CD49d, where it operates as a negative modulator of proliferation signals in substrate-adherent non-hematopoietic CD49d+ cells (Danussi et al, J Cell Biol, 2011). Here, we investigated the distribution of EMILIN1 in normal and CLL-involved tissues, and the effects of EMILIN1/CD49d interaction in CLL in terms of adhesion and survival. By taking advantage of a specific anti-human EMILIN1 monoclonal antibody (Spessotto et al, J Biol Chem, 2003), exploratory staining in reactive lymphoid tissues (tonsil) indicated a clear extracellular EMILIN1 specific reactivity in the outer zone of the mantle/marginal areas. When investigated in lymph node tissues from CLL cases (n=3) by both immunohistochemical and immunofluorescence analyses, a clear EMILIN1 positive staining was detected intermingled with the neoplastic component. To verify whether EMILIN1 could promote CLL cell adhesion, we took advantage of the CLL-derived CD49d+ Mec-1 CLL-like cell model, previously demonstrated by us to adhere to both VCAM-1 and FN (Zucchetto et al, Leukemia, 2012). Results demonstrated similar adhesion levels of Mec-1 cells on VCAM-1, CS-1 fragment of FN and the gC1q-like EMILIN1 domain (mean number of adherent cells per field 267±24, 272±7 and 317±21, respectively).Consistently, adhesion experiments with primary CLL cells characterized by high and homogeneous CD49d expression confirmed similar levels of adhesion on both VCAM-1 and EMILIN1 (mean number of adherent cells per field 141±55 and 135±76, respectively). In all cases adhesion was specifically blocked by pre-treatment with the anti-CD49d HP1/2 blocking antibody. Immunofluorescence analysis with Mec-1 and primary CLL cells showed the recruitment of phospho-Vav-1 at the CD49d/EMILIN1 adhesion sites, with concomitant F-actin reorganization, confirming the activation of the integrin signalling pathway. The effects of EMILIN1/CD49d interactions in CLL were next investigated performing short-term adhesion experiments (2 and 5 minutes) on gC1q-like EMILIN1 domain and VCAM-1 using CLL cells from three CD49d+ cases, and verifying the phosphorylation of Akt and ERK1/2 kinases, key mediators of survival signals by western blotting. In all cases, an increased intensity of Akt and ERK1/2 phosphorylation was documented after two-minutes of adhesion on both EMILIN1 (mean fold increase =1.2±0.1, and =5.0±1.0 as compared to controls, respectively) and VCAM-1 (mean fold increase =1.6±0.2, and =4.0±1.9, respectively). The phosphorylation was even greater after five minutes (mean fold increase =2.4±0.5, and =10.0±4.0, for EMILIN1 and =2.4±0.6 and =5.0±0.7 for VCAM-1, respectively). The concomitant increase of phospho-Vav-1 confirmed the activation of the integrin signalling pathway. Finally, we verified whether CD49d/EMILIN1 interaction was able to protect CLL cells from spontaneous apoptosis, by culturing purified cells from 6 CLL cases on gC1q-like EMILIN1 domain, VCAM-1, or control substrate (1% BSA), and checking cell viability after 5 days. Both VCAM-1 and EMILIN1 were able to protect CLL cells from spontaneous apoptosis (p=0.03 and p=0.001, respectively), the viability obtained on EMILIN1 being also significantly higher than that observed on VCAM-1 (p=0.007). In conclusion, we showed here for the first time that EMILIN1 is present in normal and CLL-involved lymphoid tissues, and it is able to efficiently bind to CD49d, as expressed by CLL cells. At variance of what demonstrated in non-hematopoietic models, EMILIN1 was shown to be able to deliver anti-apoptotic/pro-survival signals to circulating CLL cells. EMILIN1/CD49d interactions may have a role in the maintenance of the neoplastic clone in CD49d-expressing CLL. Disclosures: No relevant conflicts of interest to declare." @default.
• W2597884013 created "2017-04-07" @default.
• W2597884013 creator A5008340388 @default.
• W2597884013 creator A5008348763 @default.
• W2597884013 creator A5012114658 @default.
• W2597884013 creator A5015790909 @default.
• W2597884013 creator A5020633332 @default.
• W2597884013 creator A5024701143 @default.
• W2597884013 creator A5025869007 @default.
• W2597884013 creator A5028533961 @default.
• W2597884013 creator A5034393745 @default.
• W2597884013 creator A5036223053 @default.
• W2597884013 creator A5038481656 @default.
• W2597884013 creator A5039006383 @default.
• W2597884013 creator A5041745367 @default.
• W2597884013 creator A5056634710 @default.
• W2597884013 creator A5064181453 @default.
• W2597884013 creator A5068535005 @default.
• W2597884013 creator A5073179633 @default.
• W2597884013 creator A5091091710 @default.
• W2597884013 date "2012-11-16" @default.
• W2597884013 modified "2023-10-11" @default.
• W2597884013 title "The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells" @default.
• W2597884013 doi "https://doi.org/10.1182/blood.v120.21.1772.1772" @default.
• W2597884013 hasPublicationYear "2012" @default.
• W2597884013 type Work @default.
• W2597884013 sameAs 2597884013 @default.
• W2597884013 citedByCount "0" @default.
• W2597884013 crossrefType "journal-article" @default.
• W2597884013 hasAuthorship W2597884013A5008340388 @default.
• W2597884013 hasAuthorship W2597884013A5008348763 @default.
• W2597884013 hasAuthorship W2597884013A5012114658 @default.
• W2597884013 hasAuthorship W2597884013A5015790909 @default.
• W2597884013 hasAuthorship W2597884013A5020633332 @default.
• W2597884013 hasAuthorship W2597884013A5024701143 @default.
• W2597884013 hasAuthorship W2597884013A5025869007 @default.
• W2597884013 hasAuthorship W2597884013A5028533961 @default.
• W2597884013 hasAuthorship W2597884013A5034393745 @default.
• W2597884013 hasAuthorship W2597884013A5036223053 @default.
• W2597884013 hasAuthorship W2597884013A5038481656 @default.
• W2597884013 hasAuthorship W2597884013A5039006383 @default.
• W2597884013 hasAuthorship W2597884013A5041745367 @default.
• W2597884013 hasAuthorship W2597884013A5056634710 @default.
• W2597884013 hasAuthorship W2597884013A5064181453 @default.
• W2597884013 hasAuthorship W2597884013A5068535005 @default.
• W2597884013 hasAuthorship W2597884013A5073179633 @default.
• W2597884013 hasAuthorship W2597884013A5091091710 @default.
• W2597884013 hasConcept C153911025 @default.
• W2597884013 hasConcept C16224149 @default.
• W2597884013 hasConcept C185592680 @default.
• W2597884013 hasConcept C189165786 @default.
• W2597884013 hasConcept C203014093 @default.
• W2597884013 hasConcept C2777938653 @default.
• W2597884013 hasConcept C2778461978 @default.
• W2597884013 hasConcept C502942594 @default.
• W2597884013 hasConcept C86492073 @default.
• W2597884013 hasConcept C86803240 @default.
• W2597884013 hasConcept C95444343 @default.
• W2597884013 hasConceptScore W2597884013C153911025 @default.
• W2597884013 hasConceptScore W2597884013C16224149 @default.
• W2597884013 hasConceptScore W2597884013C185592680 @default.
• W2597884013 hasConceptScore W2597884013C189165786 @default.
• W2597884013 hasConceptScore W2597884013C203014093 @default.
• W2597884013 hasConceptScore W2597884013C2777938653 @default.
• W2597884013 hasConceptScore W2597884013C2778461978 @default.
• W2597884013 hasConceptScore W2597884013C502942594 @default.
• W2597884013 hasConceptScore W2597884013C86492073 @default.
• W2597884013 hasConceptScore W2597884013C86803240 @default.
• W2597884013 hasConceptScore W2597884013C95444343 @default.
• W2597884013 hasLocation W25978840131 @default.
• W2597884013 hasOpenAccess W2597884013 @default.
• W2597884013 hasPrimaryLocation W25978840131 @default.
• W2597884013 hasRelatedWork W1533598723 @default.
• W2597884013 hasRelatedWork W191932600 @default.
• W2597884013 hasRelatedWork W1967066433 @default.
• W2597884013 hasRelatedWork W1974464160 @default.
• W2597884013 hasRelatedWork W2028936731 @default.
• W2597884013 hasRelatedWork W2095185412 @default.
• W2597884013 hasRelatedWork W2101358472 @default.
• W2597884013 hasRelatedWork W2117721992 @default.
• W2597884013 hasRelatedWork W2130900585 @default.
• W2597884013 hasRelatedWork W2185742162 @default.
• W2597884013 hasRelatedWork W2325437947 @default.
• W2597884013 hasRelatedWork W2365424488 @default.
• W2597884013 hasRelatedWork W2390514516 @default.
• W2597884013 hasRelatedWork W2561864108 @default.
• W2597884013 hasRelatedWork W2589020069 @default.
• W2597884013 hasRelatedWork W2789699824 @default.
• W2597884013 hasRelatedWork W2971906662 @default.
• W2597884013 hasRelatedWork W2979531654 @default.
• W2597884013 hasRelatedWork W3187427232 @default.
• W2597884013 hasRelatedWork W2182021686 @default.
• W2597884013 isParatext "false" @default.
• W2597884013 isRetracted "false" @default.
• W2597884013 magId "2597884013" @default.
• W2597884013 workType "article" @default.